CAS 150915-40-5|Tirofiban hydrochloride
| Common Name | Tirofiban hydrochloride | ||
|---|---|---|---|
| CAS Number | 150915-40-5 | Molecular Weight | 495.073 |
| Density | / | Boiling Point | 611.7ºC at 760 mmHg |
| Molecular Formula | C22H39ClN2O6S | Melting Point | 135-137ºC |
| MSDS | ChineseUSA | Flash Point | 323.7ºC |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | tirofiban hydrochloride |
|---|---|
| Synonym | More Synonyms |
Tirofiban hydrochloride BiologicalActivity
| Description | Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonistIC50 value:Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation. Tirofiban is an antithrombotic used in the treatment of unstable angina.Tirofiban, in a concentration-dependent manner reduced platelet aggregation evoked by ADP (IC50 approximately 70 ng/ml), collagen (IC50 approximately 200 ng/ml), and thrombin (IC50 approximately 5,000 ng/ml). |
|---|---|
| Related Catalog | Signaling Pathways >>Cytoskeleton >>IntegrinResearch Areas >>Cardiovascular Disease |
| References | [1]. Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. [2]. van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. [3]. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. [4]. Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. [5]. Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. |
Chemical & Physical Properties
| Boiling Point | 611.7ºC at 760 mmHg |
|---|---|
| Melting Point | 135-137ºC |
| Molecular Formula | C22H39ClN2O6S |
| Molecular Weight | 495.073 |
| Flash Point | 323.7ºC |
| Exact Mass | 494.221741 |
| PSA | 122.34000 |
| LogP | 5.48870 |
| InChIKey | HWAAPJPFZPHHBC-FGJQBABTSA-N |
| SMILES | CCCCS(=O)(=O)NC(Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O.Cl.O |
| Storage condition | -20°C Freezer |
| Water Solubility | DMSO: >12mg/mL at warmed to 60°C |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-37-45 |
| RIDADR | NONH for all modes of transport |
Articles1
More Articles| Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose. J. Clin. Lab Anal. 30 , 108-13, (2016) Activated clotting time (ACT) has been successfully applied during percutaneous coronary intervention (PCI) to monitor the extent of thrombin inhibition and anti-coagulation from unfractionated hepari... |
Synonyms
| L 700462 MK 383 N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine |
| N-(butylsulfonyl)- O-[4-(4-piperidinyl)butyl]-L-tyrosine monohydrochloride monohydrate |
| N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]tyrosine hydrochloride hydrate |
| N-(Butylsulfonyl)-O-[4-(piperidin-4-yl)butyl]-L-tyrosine hydrochloride hydrate |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid,hydrate,hydrochloride |
| Tirofiban hydrochloride |
| Tirofiban hydrochloride monohydrate |
| tirofiban hydrochloride anhydrous |
| Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, hydrochloride, hydrate (1:1:1) |
| Tirofiban Hydrochloride Hydrate |
| Tirofiban (hydrochloride monohydrate) |
